Catalent Launches Qai Enterprise AI Platform to Strengthen Quality Management Operations

Catalent Inc., the global contract development and manufacturing organization (CDMO), has launched Qai. Their first enterprise level AI platform that delivers enhanced quality management capabilities. The solution is smart, effortless to implement, and seamlessly integrates into existing quality processes to shorten investigations and bolster consistency.

Enhance decision-making across the entire pharmaceutical manufacturing process. The launch is part of Catalent's digital transformation journey. Life sciences companies are increasingly turning to AI for improved operational excellence and regulatory compliance. Qai helps in a wide range of enterprise quality management activities, such as handling deviations, conducting root cause analysis, and planning corrective and preventive actions.

The platform's AI capabilities help to speed up the assessment process without compromising on quality. They also maintain uniformity in adherence to established standards across various manufacturing sites. Additionally, the project underscores the pivotal position of AI technologies in contemporary pharmaceutical manufacturing, where efficiency and quality control are important.

According to Precedence Research the global AI in CGT Manufacturing Market size accounted for USD 412.00 million in 2025 and is predicted to increase from USD 531.07 million in 2026 to approximately USD 5,217.07 million by 2035, expanding at a CAGR of 28.90% from 2026 to 2035. Market growth is attributed to the increasing commercialization of cell and gene therapies and growing investments in AI-driven process optimization across advanced therapy production facilities.

AI-Driven Quality Insights Improve Manufacturing Decision-Making

Qai has been designed to empower existing quality management systems. They offer intelligent suggestions and integrate seamlessly into operational processes as the user goes about their daily tasks. The platform is designed to augment the existing quality processes by analyzing enterprise data to find trends and suggest possible corrective actions. This comprehensive solution empowers quality teams with quicker decision-making without impacting certified manufacturing.

It speeds up root cause investigations by analyzing real-time manufacturing events with historic operational data. Prioritizing the factors that can cause a deviation means that it can be reduced or prevented the next time. It occurs and can make corrective and preventive action programs more effective. But constant analytical assistance will reduce the difference in investigations from plant to plant.

The company believes the platform contributes to its operational efficiency. It enables quality professionals to focus more on higher-value activities, such as scientific and manufacturing. Common analytical tasks can be carried out more efficiently, allowing more experienced staff to be available for more in-depth technical evaluations for improving projects.

Digital Transformation Supports Future Pharmaceutical Manufacturing

Qai's launch marks Catalent's continued use of cutting-edge digital technologies across their manufacturing assets. Companies strive to gain a deeper level of insight and more consistent decision-making in the highly regulated environment of pharma manufacturing. AI is now fundamentally helping to become an integral part of the production process. Furthermore, AI is helping companies modernize their old quality systems without compromising the expectations for compliance.

The partnership indicates growing partnerships between pharma companies and technology providers. They are driving forward digital innovation for regulated manufacturing environments. Cloud-based AI-powered systems offer the necessary computing power to handle intricate manufacturing data and stay powerful in governance and working safety.

AI technologies are spreading from research and drug discovery to commercial manufacturing in the life sciences. Timely Investigations, correct documentation, and adequate corrective actions directly impact manufacturing efficiency and regulatory compliance. 

Thereby establishing quality management systems as an important application. AI-based analytics are thus powerful tools for enhancing quality control systems, but not for moving away from regulatory compliance. Furthermore, the shift toward organizations' demands of increasing their use of data for operational intelligence is also represented by the emergence of Qai.